Plus Therapeutics Sets 2026 Milestones for REYOBIQ Clinical Program and CNSide Commercial Launch - PLTX

Plus Therapeutics Inc. announced key 2026 milestones for its REYOBIQ clinical development program and the commercial rollout of CNSide, a targeted therapy for central nervous system (CNS) cancers, on January 22, 2026. The company outlined plans to complete Phase 3 trials for REYOBIQ by mid-2026, with regulatory submission expected in the fourth quarter of the year. The clinical program will focus on demonstrating efficacy and safety in patients with recurrent glioblastoma. Concurrently, Plus Therapeutics intends to launch CNSide in the U.S. market by December 2026, pending FDA approval. The company reported that CNSide has shown promising response rates in early-phase trials, with an overall response rate of 42% in a Phase 2 study. Financial details were not disclosed, but the company expects significant revenue potential from CNSide’s commercialization. Shares of Plus Therapeutics (PLTX) rose 5.7% following the announcement, trading at $18.30 as of 15:00 UTC on January 22, 2026.